Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Net Cash Flow (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Net Cash Flow for 10 consecutive years, with -$1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 61.36% to -$1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$13.6 million, a 340.96% decrease, with the full-year FY2024 number at -$4.5 million, down 136.72% from a year prior.
  • Net Cash Flow was -$1.6 million for Q3 2025 at Rein Therapeutics, up from -$1.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $11.7 million in Q1 2021 to a low of -$8.5 million in Q2 2021.
  • A 5-year average of -$184315.8 and a median of -$1.6 million in 2025 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 397.89% in 2021, then skyrocketed 2907.82% in 2023.
  • Rein Therapeutics' Net Cash Flow stood at -$4.0 million in 2021, then surged by 108.87% to $355000.0 in 2022, then soared by 1394.93% to $5.3 million in 2023, then crashed by 190.65% to -$4.8 million in 2024, then soared by 65.75% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Net Cash Flow are -$1.6 million (Q3 2025), -$1.7 million (Q2 2025), and -$5.4 million (Q1 2025).